Cell squeezing technology offers new breast cancer risk assessment: A revolutionary approach to early detection
In a groundbreaking development, researchers at City of Hope and the University of California, Berkeley, have unveiled a novel microfluidic platform that could revolutionize breast cancer risk assessment. This innovative technology, dubbed 'MechanoAge', utilizes cell squeezing to measure how breast epithelial cells deform, recover, and behave under stress, providing a more accurate and personalized risk assessment.
The study, published in Lancet's eBioMedicine, highlights the potential of this approach to fill a critical gap in risk assessment, especially for women without a known genetic predisposition or family history of breast cancer. By translating physical changes in cells into quantifiable data, MechanoAge offers women a tangible way to discuss their risk with doctors, moving beyond mere risk estimates.
What makes this technology particularly exciting is its simplicity and affordability. Unlike other methods that require advanced imaging technology, MechanoAge uses computer chips that are simpler than an Apple Watch and easily replicable on a large scale. This scalability is crucial for widespread adoption and could potentially save countless lives.
The research team developed a machine learning algorithm that identifies and measures cells showing signs of accelerated aging, quantifying an individual breast cancer risk score. This algorithm successfully identified women with known genetic risks and those with a family history of breast cancer, demonstrating its accuracy and potential for early detection.
One of the most fascinating findings was the discovery of a 'mechanical age' in breast cells, separate from chronological age. This mechanical age, determined by how cells respond to being squeezed through the microfluidic device, is directly linked to breast cancer risk. The older the mechanical age, the higher the risk, providing a new avenue for understanding and potentially preventing breast cancer.
The MechanoAge platform operates through a mechano-node-pore sensing technique, measuring electrical current across a liquid-filled channel as cells pass through. By making parts of the channel very narrow, researchers can squeeze cells and measure their recovery time, providing insights into their size and shape.
The study revealed that physical properties of breast cells change with age, with cells from older women being stiffer and taking longer to bounce back after squeezing. Interestingly, a subset of younger women had cells that behaved like those from older women, indicating a genetic predisposition to breast cancer. This finding highlights the potential of MechanoAge to identify high-risk individuals early on.
The long-term collaboration between the two research institutions has been instrumental in this breakthrough. By combining engineering innovation with cancer and aging biology, the team has made significant strides in understanding breast cancer risk. This collaborative effort is a testament to the power of interdisciplinary research.
In conclusion, the development of MechanoAge represents a significant step forward in breast cancer risk assessment. Its simplicity, affordability, and accuracy make it a promising tool for early detection, potentially saving lives and improving outcomes for women at risk of breast cancer. As research continues, MechanoAge may become a standard part of breast cancer screening protocols, offering a more personalized and effective approach to prevention and treatment.
